We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
iBio Inc | AMEX:IBIO | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.02 | 0.99% | 2.05 | 2.15 | 2.01 | 2.03 | 132,260 | 18:05:30 |
In addition to participating in a series of one-on-one meetings with institutional investors throughout the day, iBio will participate on a panel hosted by Jim Molloy, Alliance Global Partners’ Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals, entitled “The Next Wave in COVID-19 Treatments: After PFE, AZN, MRNA & the Rest, What Should we Look for in the Next Set of COVID-19 Diagnostics and Treatments?”
Due to the format of the event, no webcast will be available.
About iBio, Inc.
iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBio’s Glycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, and vaccines for infectious diseases. For more information, visit www.ibioinc.com.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646) 274-3580 skilmer@ibioinc.com
1 Year iBio Chart |
1 Month iBio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions